Cancer Targeted Technologies

Cancer Targeted Technologies (CTT) is a clinical-stage biotechnology company developing a pipeline of small-molecule radiopharmaceuticals for the diagnosis and treatment of prostate cancer. The company's proprietary platform utilizes phosphoramidate-based ligands that bind irreversibly to Prostate-Specific Membrane Antigen (PSMA), a protein highly expressed in prostate cancer cells. This unique irreversible binding mechanism is designed to improve tumor-to-background ratios, leading to more accurate imaging and more effective delivery of therapeutic isotopes. CTT's lead programs include CTT1057, an 18F-labeled PET imaging agent in Phase 2, and CTT1403, a 177Lu-labeled therapeutic in Phase 1. The company follows a theranostic approach, pairing diagnostic imaging with targeted radiotherapy to personalize patient care. CTT is headquartered in Woodinville, Washington, and has received significant support from the National Cancer Institute through SBIR grants.